Revenue Update on Galena Biopharma Inc(NASDAQ:GALE)

Galena Biopharma Inc(NASDAQ:GALE) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.17. The reported EPS was above estimates by 67.31%. Analysts had estimated an EPS of $-0.52.

In a different note, On Feb 6, 2017, FBR Capital said it Downgrades its rating on Galena Biopharma Inc. According to the research note, FBR Capital Lowers the price target to $4 per share from a prior target of $11. The shares have been rated ‘Market Weight’ by the firm. On Feb 2, 2017, Maxim Group said it Downgrades its rating on Galena Biopharma Inc. The shares have been rated ‘Hold’ by the firm.

Galena Biopharma Inc (GALE) made into the market gainers list on Fridays trading session with the shares advancing 0.85% or 0.0053 points. Due to strong positive momentum, the stock ended at $0.6253, which is also near the day’s high of $0.8081. The stock began the session at $0.73 and the volume stood at 1,44,91,847 shares. The 52-week high of the shares is $49.802 and the 52 week low is $0.53. The company has a current market capitalization of $22 M and it has 3,59,21,324 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 7, 2016, Ryan Dunlap (Former Chief Financial Officer) sold 126,875 shares at $2.18 per share price.

Galena Biopharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets including immunotherapy program led by its lead product NeuVax (nelipepimut-S) which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Add Comment